Company Overview and News


Add AVXS
to your dashboard

Headline News

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

2017-11-21 seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-6)

AVXS / AveXis, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-14 fintel.io
AveXis, Inc. (NASDAQ:AVXS) has 136 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32,996,708 shares. Largest shareholders include FMR LLC / Fidelity Management & Research, Deerfield Management Co, BlackRock Inc., Vanguard Group Inc, and Flynn James E. (45-0)

AveXis' (AVXS) CEO Sean Nolan on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the AveXis Conference Call to discuss Third Quarter Financial and Operating Results as well as recent Corporate Highlights and Upcoming Milestones. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (65-2)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

AveXis: Revolutionary Cure For SMA1 Enters Phase III Trials With Excitement Mounting

2017-11-02 seekingalpha
Pricing of the treatment is creating excitement among shareholders - strong potential returns over the next 3 years. (81-1)

Emergence Of A Novel Gene Therapy Mechanism: Krystal Biotech

2017-11-02 seekingalpha
Krystal Biotech is entering into clinical trials with two topical gene therapy agents for rare and debilitating dermatological diseases. (30-0)

Biogen: Analysis Of Q3 And Recent Events

2017-10-25 seekingalpha
Caution on BIIB's dominant MS franchise's implied valuation makes me think that the stock is unattractive to new money investors at its current price above $300. (96-0)

Biogen Has an MS Meltdown Coming - Bloomberg Gadfly

2017-10-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (268-0)

Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval

2017-10-13 seekingalpha
An FDA Ad Com recommended approval for ONCE’s gene therapy for biallelic RPE65-mediated inherited retinal disease. (693-4)

Your Daily Pharma Scoop: AcelRx DSUVIA PDUFA, Ardelyx Phase 3 Success, Rhopressa, LUXTURNA Adcomm Tomorrow

2017-10-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (414-3)

BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101

2017-10-03 reuters
* AveXis to report top-line data from the Phase 1 clinical trial of AVXS-101 in SMA Type 1 at the International Annual Congress Of The World Muscle Society (13-0)

Featured Company News - AveXis Intends To Initiate Pivotal Trial Of AVXS-101 In SMA Type 1 On An Immediate Basis

2017-10-03 accesswire
LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AveXis, Inc. (NASDAQ: AVXS), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=AVXS. The Company announced on September 29, 2017, that the US Food and Drug Administration (FDA) has notified AveXis that it may initiate a pivotal trial of AVXS-101. (28-0)

BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1

2017-09-29 reuters
* Avexis announces plan to initiate pivotal trial of AVXS-101 in SMA type 1 using product from new GMP commercial process (13-0)

Rtw Investments, Llc - Current Holdings - Fintel.io

2017-09-28 fintel.io
Rtw Investments, Llc has disclosed 28 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 265,662,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Rtw Investments, Llc's top holdings are Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , PTC Therapeutics, Inc. (NASDAQ:PTCT) , AveXis, Inc. (NASDAQ:AVXS) , Bristol-Myers Squibb Co. (118-0)

AveXis' (AVXS) CEO Sean Nolan on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the AveXis Conference Call to discuss Second Quarter Financial and Operating Results as well as the recent Corporate Highlights and Upcoming Milestones. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.

CUSIP: 05366U100